Acute Effects of Coffee on Appetite and Inflammation Markers, Glucose Metabolism and Energy Intake
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to investigate whether caffeinated and decaffeinated coffee consumption has acute effects on subjective appetite feelings, energy intake and biochemical markers related to appetite, inflammation and glucose metabolism compared to water consumption.
| Condition | Intervention |
|---|---|
|
Health |
Other: caffeinated and decaffeinated coffee |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | Acute Effects of Caffeinated and Decaffeinated Coffee Consumption on Energy Intake, Appetite, Inflammation and Glucose Metabolism |
- markers of appetite [ Time Frame: fasting (-15 min) ] [ Designated as safety issue: No ]
- markers of appetite [ Time Frame: immediately after breakfast consumption (0 min) ] [ Designated as safety issue: No ]
- markers of appetite [ Time Frame: 15 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of appetite [ Time Frame: 30 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of appetite [ Time Frame: 60 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of appetite [ Time Frame: 90 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of appetite [ Time Frame: 120 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of appetite [ Time Frame: 150 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of appetite [ Time Frame: 180 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of inflammation [ Time Frame: fasting (-15 min) ] [ Designated as safety issue: No ]
- markers of inflammation [ Time Frame: 30 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of inflammation [ Time Frame: 60 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of inflammation [ Time Frame: 90 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of inflammation [ Time Frame: 120 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of inflammation [ Time Frame: 150 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of inflammation [ Time Frame: 180 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of glucose metabolism [ Time Frame: fasting (-15 min) ] [ Designated as safety issue: No ]
- markers of glucose metabolism [ Time Frame: immediately after breakfast consumption (0 min) ] [ Designated as safety issue: No ]
- markers of glucose metabolism [ Time Frame: 15 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of glucose metabolism [ Time Frame: 30 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of glucose metabolism [ Time Frame: 60 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of glucose metabolism [ Time Frame: 90 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of glucose metabolism [ Time Frame: 120 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of glucose metabolism [ Time Frame: 150 min after breakfast consumption ] [ Designated as safety issue: No ]
- markers of glucose metabolism [ Time Frame: 180 min after breakfast consumption ] [ Designated as safety issue: No ]
- energy intake [ Time Frame: ad libitum meal (180 min after breakfast consumption) ] [ Designated as safety issue: No ]
- energy intake [ Time Frame: rest of the day (total day after the 4h experiment) ] [ Designated as safety issue: No ]
- macronutrient intake [ Time Frame: ad libitum meal (180 min after breakfast consumption) ] [ Designated as safety issue: No ]
- macronutrient intake [ Time Frame: rest of the day (total day after the 4h experiment) ] [ Designated as safety issue: No ]
- oxidative status [ Time Frame: fasting (-15 min) ] [ Designated as safety issue: No ]
- oxidative status [ Time Frame: immediately after breakfast consumption (0 min) ] [ Designated as safety issue: No ]
- oxidative status [ Time Frame: 15 min after breakfast consumption ] [ Designated as safety issue: No ]
- oxidative status [ Time Frame: 30 min after breakfast consumption ] [ Designated as safety issue: No ]
- oxidative status [ Time Frame: 60 min after breakfast consumption ] [ Designated as safety issue: No ]
- oxidative status [ Time Frame: 90 min after breakfast consumption ] [ Designated as safety issue: No ]
- oxidative status [ Time Frame: 120 min after breakfast consumption ] [ Designated as safety issue: No ]
- oxidative status [ Time Frame: 150 min after breakfast consumption ] [ Designated as safety issue: No ]
| Enrollment: | 16 |
| Study Start Date: | February 2009 |
| Study Completion Date: | May 2009 |
| Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
-
Other: caffeinated and decaffeinated coffee
Coffee is a pharmacologically active, widely consumed beverage. Scientific interest in relation to coffee consumption has been revisited the last decade in the light of new, mainly epidemiological, evidence indicating its potential health benefits. In specific, both cross-sectional and prospective studies indicate that coffee consumption is associated with a lower risk for type 2 diabetes. Furthermore, an inverse association has been found between coffee consumption and markers of inflammation and endothelial dysfunction in healthy and/or diabetic participants, although the opposite effect has also been reported, mainly in relation to inflammation markers. In relation to body weight, epidemiological data suggest that increment in caffeine consumption is associated with lower mean weight gain and energy intake during a 12-y period.
However, information from clinical studies is scarce. Acute caffeine and/or coffee consumption have been associated with impaired glucose metabolism and insulin resistance. In relation to inflammation, animal studies have indicated a beneficial or no effect of coffee consumption, whereas a clinical study in humans found an increase in adiponectin and a decrease in interleukin-18 (IL-18) blood concentrations after a monthly intervention including daily consumption of 8 cups of coffee. As far as energy balance is concerned, there is an early experiment demonstrating that the ingestion of 300 mg of caffeine prior to food intake, compared to the non-caffeine intake, significantly reduced energy intake by 21.7% in men, but not in women. A more recent study has found that the combination of caffeine and red pepper is positively associated with energy expenditure and negatively with energy intake, whereas, it has also been reported a positive association between habitual caffeine intake and body weight loss achieved through a very-low-calorie diet.
Taking into consideration the limited clinical evidence regarding the acute effect of coffee consumption on appetite-related markers, subsequent energy intake and inflammatory markers, we undertook a clinical study of crossover design to investigate the short-term changes on energy intake, subjective appetite ratings, appetite hormones, inflammation markers and glucose metabolism after caffeinated and decaffeinated coffee consumption.
Eligibility| Ages Eligible for Study: | 18 Years to 40 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- healthy
- non-obese
Exclusion Criteria:
- smokers
- restrained eaters (as this was evaluated using the Dutch Eating Behaviour Questionnaire and a total score > 2.5)
- those who reported slimming or any other dietary regime
- abstainers from caffeine sources
- athletes during competition period
- participants with a known diagnosis of either hypertension, diabetes, impaired glucose tolerance or a fasting blood glucose concentration above 125 mg/dl
- subjects on medication for hypertension or on medication known to alter glucose metabolism
- subjects who were on medication that may have an impact on appetite and sensory functioning or who reported a metabolic or endocrine disease, gastrointestinal disorders, or a history of medical or surgical events that may have affected the study outcomes
Contacts and Locations| Greece | |
| Metabolic Unit of the Department of Nutrition and Dietetics, Harokopio University | |
| Athens, Greece, 17671 | |
| Study Director: | Mary Yannakoulia, PhD | Harokopio University |
More Information
No publications provided by Harokopio University
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Yannakoulia Mary, senior lecturer, Harokopio University |
| ClinicalTrials.gov Identifier: | NCT01174576 History of Changes |
| Other Study ID Numbers: | CofSt |
| Study First Received: | July 26, 2010 |
| Last Updated: | August 2, 2010 |
| Health Authority: | Greece: Ethics Committee |
Keywords provided by Harokopio University:
|
coffee appetite energy intake inflammation |
cortisol glucose randomized control trial |
Additional relevant MeSH terms:
|
Inflammation Pathologic Processes |
ClinicalTrials.gov processed this record on May 16, 2013